CO2017009353A2 - Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd - Google Patents

Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd

Info

Publication number
CO2017009353A2
CO2017009353A2 CONC2017/0009353A CO2017009353A CO2017009353A2 CO 2017009353 A2 CO2017009353 A2 CO 2017009353A2 CO 2017009353 A CO2017009353 A CO 2017009353A CO 2017009353 A2 CO2017009353 A2 CO 2017009353A2
Authority
CO
Colombia
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
CONC2017/0009353A
Other languages
English (en)
Spanish (es)
Inventor
Hannah Canning
Richard Davenport
Susanne Wright
Saleh Ahmed
Gregory Barker
David Harrison
Kerry Jenkins
David Livermore
Natasha Kinsella
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2017009353A2 publication Critical patent/CO2017009353A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2017/0009353A 2015-03-18 2017-09-14 Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd CO2017009353A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (1)

Publication Number Publication Date
CO2017009353A2 true CO2017009353A2 (es) 2017-11-30

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0009353A CO2017009353A2 (es) 2015-03-18 2017-09-14 Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (1) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718902C2 (ru) 2016-02-24 2020-04-15 Пфайзер Инк. Производные пиразоло[1,5-а]пиразин-4-ила в качестве jak-ингибиторов
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
US20230322717A1 (en) * 2020-04-20 2023-10-12 Shenzhen Targetrx, Inc. Solid form of pyrazine substituted nicotinamide, and preparation and use thereof
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
IL312220A (en) 2021-10-28 2024-06-01 Insilico Medicine Ip Ltd Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
JP2004502691A (ja) 2000-06-30 2004-01-29 ワイス 抗癌薬としての置換トリアゾロピリミジン
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Also Published As

Publication number Publication date
CA2979024A1 (en) 2016-09-22
DK3271357T3 (da) 2020-02-17
CR20170468A (es) 2018-04-27
HK1249512A1 (en) 2018-11-02
SG11201707280VA (en) 2017-10-30
PE20180656A1 (es) 2018-04-17
EP3271357A1 (en) 2018-01-24
ZA201706612B (en) 2019-01-30
CL2017002354A1 (es) 2018-05-04
UA123668C2 (uk) 2021-05-12
EP3271357B1 (en) 2019-11-27
CN107531698A (zh) 2018-01-02
CN107531698B (zh) 2024-08-13
MX2017011902A (es) 2017-12-15
BR112017019653B1 (pt) 2023-10-03
NZ735631A (en) 2023-07-28
GB201504565D0 (en) 2015-05-06
DOP2017000209A (es) 2017-10-15
HUE047918T2 (hu) 2020-05-28
PH12017501699A1 (en) 2018-03-12
EA201792057A1 (ru) 2018-04-30
CA2979024C (en) 2024-02-20
TN2017000384A1 (en) 2019-01-16
IL254277A0 (en) 2017-10-31
IL254277B (en) 2020-10-29
BR112017019653A2 (pt) 2018-05-15
AU2016234209A1 (en) 2017-10-12
AU2016234209B2 (en) 2020-08-27
JP2018512408A (ja) 2018-05-17
WO2016148306A1 (en) 2016-09-22
US20180072714A1 (en) 2018-03-15
US10287286B2 (en) 2019-05-14
KR102609431B1 (ko) 2023-12-04
GEP20207095B (en) 2020-04-10
MY194873A (en) 2022-12-21
EA035739B1 (ru) 2020-08-03
ES2774052T3 (es) 2020-07-16
PT3271357T (pt) 2020-02-21
KR20170129874A (ko) 2017-11-27
JP6726681B2 (ja) 2020-07-22
ECSP17069696A (es) 2018-02-28
PH12017501699B1 (en) 2023-06-30

Similar Documents

Publication Publication Date Title
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
ECSP16074478A (es) Compuestos novedosos
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
ECSP17083003A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY35536A (es) ?derivados de sulfonamida?.
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
ECSP18056196A (es) Derivados de indano
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos